{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Perioperative Gabapentin for Postoperative Pain and Opioid Cessation"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "randomised, double-blind, placebo-controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "A total of 1805 patients aged 18 to 75 years scheduled for surgeries such as thoracotomy, total hip replacement, and mastectomy were screened."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Gabapentin (1200 mg preoperatively and 600 mg three times daily postoperatively) was compared to an active placebo (lorazepam, 0.5 mg preoperatively followed by inactive placebo postoperatively for 72 hours)."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was time to pain resolution, defined as five consecutive reports of zero pain at the surgical site."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Patients, clinicians, and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Participants were enrolled from May 25, 2010, to July 25, 2014, and followed for 2 years."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "422 were randomised: 202 to placebo and 208 to gabapentin. Intention-to-treat analysis showed no effect on pain cessation"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Intention-to-treat analysis showed no effect on pain cessation (HR, 1.04; 95% CI, 0.82-1.33; P = .73) but a 24% increase in opioid cessation rate (HR, 1.24; 95% CI, 1.00-1.54; P = .05)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with sedation or dizziness leading to medication discontinuation in 20.8% of placebo and 25.0% of gabapentin patients."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "NCT01067144"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 23,
    "max_score": 25
  },
  "model": "gpt-4o"
}